These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 10893659)

  • 1. Treating osteoarthritis in practice--the TOP Study.
    Knott L
    Curr Med Res Opin; 2000; 16(2):147-52. PubMed ID: 10893659
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Appropriateness of NSAID and Coxib prescribing for patients with osteoarthritis by primary care physicians in Ontario: results from the CANOAR study.
    Sebaldt RJ; Petrie A; Goldsmith CH; Marentette MA
    Am J Manag Care; 2004 Nov; 10(11 Pt 1):742-50. PubMed ID: 15623264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Motivations and perceived influences on rural and urban general practitioners when prescribing conventional non-steroidal anti-inflammatory drugs or COX-2 inhibitors.
    Behan K; Cutts C; Tett SE
    J Clin Pharm Ther; 2005 Aug; 30(4):337-43. PubMed ID: 15985047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nonsteroidal therapy of rheumatoid arthritis and osteoarthritis: how physicians manage treatment failures.
    Spencer-Green G; Spencer-Green E
    J Rheumatol; 1998 Nov; 25(11):2088-93. PubMed ID: 9818649
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Valdecoxib is associated with improved dyspepsia-related health compared with nonspecific NSAIDs in patients with osteoarthritis or rheumatoid arthritis.
    Rabeneck L; Goldstein JL; Vu A; Mayne TJ; Rublee DA
    Am J Gastroenterol; 2005 May; 100(5):1043-50. PubMed ID: 15842577
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Results from a patient survey to assess gastrointestinal burden of non-steroidal anti-inflammatory drug therapy contrasted with a review of data from EVA to determine satisfaction with rofecoxib.
    Steinfeld S; Bjørke PA
    Rheumatology (Oxford); 2002 Apr; 41 Supp 1():23-7; discussion 35-42. PubMed ID: 12173277
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A regional audit of the use of COX-2 selective non-steroidal anti-inflammatory drugs (NSAIDs) in rheumatology clinics in the West Midlands, in relation to NICE guidelines.
    Price-Forbes AN; Callaghan R; Allen ME; Rowe IF
    Rheumatology (Oxford); 2005 Jul; 44(7):921-4. PubMed ID: 15827035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New directions in symptomatic therapy for patients with osteoarthritis and rheumatoid arthritis.
    Hochberg MC
    Semin Arthritis Rheum; 2002 Dec; 32(3 Suppl 1):4-14. PubMed ID: 12528069
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gender differences in NSAID use among older adults with osteoarthritis.
    Dominick KL; Ahern FM; Gold CH; Heller DA
    Ann Pharmacother; 2003 Nov; 37(11):1566-71. PubMed ID: 14565813
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GP and patient perspectives on treatment with non-steroidal anti-inflammatory drugs for the treatment of pain in osteoarthritis.
    Crichton B; Green M
    Curr Med Res Opin; 2002; 18(2):92-6. PubMed ID: 12017216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A cross-sectional retrospective assessment of anti-arthritic drugs in patients with arthritis in Korea.
    Lee MC; Lee S; Suh DC; Kim J; Kong SX;
    Curr Med Res Opin; 2003; 19(7):597-602. PubMed ID: 14606981
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prescribing behaviors of family physicians in the treatment of osteoarthritis.
    Holt WS; Mazzuca SA
    Fam Med; 1992; 24(7):524-7. PubMed ID: 1397826
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The comparative risk and predictors of adverse gastrointestinal events in rheumatoid arthritis and osteoarthritis: a prospective 13 year study of 2131 patients.
    Wolfe F; Hawley DJ
    J Rheumatol; 2000 Jul; 27(7):1668-73. PubMed ID: 10914849
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rates of serious gastrointestinal events from low dose use of acetylsalicylic acid, acetaminophen, and ibuprofen in patients with osteoarthritis and rheumatoid arthritis.
    Fries JF; Bruce B
    J Rheumatol; 2003 Oct; 30(10):2226-33. PubMed ID: 14528521
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient and physician satisfaction with rofecoxib in osteoarthritis: results of the EVA (experience with VIOXX in arthritis) survey.
    Steinfeld S; Poriau S
    Curr Med Res Opin; 2001; 17(2):81-7. PubMed ID: 11759186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis.
    Maetzel A; Krahn M; Naglie G
    Arthritis Rheum; 2003 Jun; 49(3):283-92. PubMed ID: 12794781
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of selective cyclooxygenase-2 inhibitors on anti-ulcer medication and non-steroidal anti-inflammatory drug use in patients with rheumatic disease.
    Joshua FF; Oakley SP; Major GA
    Intern Med J; 2004 Apr; 34(4):153-61. PubMed ID: 15086694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An evidence-based approach to prescribing nonsteroidal antiinflammatory drugs. Third Canadian Consensus Conference.
    Tannenbaum H; Bombardier C; Davis P; Russell AS;
    J Rheumatol; 2006 Jan; 33(1):140-57. PubMed ID: 16331802
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Verification of a decision analytic model assumption using real-world practice data: implications for the cost effectiveness of cyclo-oxygenase 2 inhibitors (COX-2s).
    Cox ER; Motheral B; Mager D
    Am J Manag Care; 2003 Dec; 9(12):785-94. PubMed ID: 14712755
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of aceclofenac in the treatment of osteoarthritis: a randomized double-blind comparative clinical trial versus diclofenac - an Indian experience.
    Pareek A; Chandanwale AS; Oak J; Jain UK; Kapoor S
    Curr Med Res Opin; 2006 May; 22(5):977-88. PubMed ID: 16709320
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.